Prognostic Model for Predicting Survival in Patients with Disease Recurrence Following Radical Cystectomy

Kluth, Luis A.; Xylinas, Évanguelos; Rieken, Malte; Kent, Matthew; Ikeda, Masaomi; Matsumoto, Kazumasa; Hagiwara, Masaru; Bing, Megan T.; Gupta, Amit; Sewell, Joseph M.; Konety, Badrinath R.; Todenhöfer, Tilman; Schwentner, Christian; Masson-Lecomte, A.; Vordos, Dimitri; Roghmann, Florian; Noldus, Joachim; Razmaria, Aria; Smith, Norm D.; Comploj, Evi; Pycha, Armin; Rink, Michael; Baniel, Jack; Novara, Giacomo; Aziz, Atiqullah; Fritsche, Hans Martin; Brisuda, A.; Bivalacqua, Trinity J.; Boorjian, Stephen A.; Vickers, Andrew J.; Shariat, Shahrokh F.

doi:10.1016/j.euf.2014.10.003

Cited by 7 publications

(3 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Liver involvement is far from rare for mBC and provides worst survival outcomes [ 5 ]; however, it was reported in only three mNMIBC cases. Time to relapse, or MFS interval, is a survival prognostic factor for mBC following radical cystectomy [ 28 ]. MFS intervals of MIBC-dominated cohorts are around 1–2 years [ 26 , 29 ].…”

Section: Discussionmentioning

confidence: 99%

Distant metastasis without regional progression in non-muscle invasive bladder cancer: case report and pooled analysis of literature

Wang

et al. 2022

World J Surg Onc

View full text Add to dashboard Cite

Background Non-muscle invasive bladder cancer (NMIBC) represents the majority of bladder neoplasms. It is unusual for NMIBC metastasizing distantly without regional progression, namely metastatic NMIBC (mNMIBC), which is still poorly understood and easily omitted based on current management policies. So far, description of mNMIBC is limited to a few case reports. Methods We reported a 70-year-old man with NMIBC who suffered from cervical metastasis without pelvic recurrence at 41 months after initial diagnosis. Then we performed a collective analysis of this case together with published mNMIBC cases searched from PubMed, Embase, and Web of Science, aiming to illustrate baseline clinicopathologic parameters, metastatic patterns, and treatment outcomes of these patients and analyze associated influencing factors. Results After scrupulous review, 45 cases previous reported and the one from our center were incorporated into the aggregated cohort of mNMIBC, including 34 males and 12 females. Primary tumors from 46.7% of patients were high-grade (HG) or grade 3 (G3) and 65.1% had T1 lesions. Aberrant biomarker expression was found in tumors of some cases. Most (40/46) metastases of mNMIBC occurred at a single site, mainly in lung, bone and lymph nodes. Apart from three cases of de novo mNMIBC, the mean metastasis-free survival (MFS) interval of metachronous mNMIBC was 42.5 months, which was obviously longer than conventional metastatic bladder cancer. Shortened MFS interval was associated with old age, T1 or HG/G3 primary tumors, and non-lung metastases. Systemic chemotherapy and metastasectomy or radiotherapy for oligometastatic lesion were main therapeutic approaches of mNMIBC, and immunotherapy was adopted for the case from our center. Lung and bone metastases correlated with relatively favorable and unfavorable survival outcomes, respectively. Compared with monotherapy, chemotherapy, or immunotherapy combined with local cytoreduction got more favorable outcomes. Conclusion Although rare, mNMIBC occurs more in tumors with high-risk features. Usually, mNMIBC metastasizes later than conventional metastatic bladder cancer and manifests as solitary lesion. Outcomes of mNMIBC would be influenced by metastatic site and post-metastatic treatment. Systemic treatment combined with local cytoreduction may render survival benefit in selected patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Distant metastasis without regional progression in non-muscle invasive bladder cancer: case report and pooled analysis of literature

Wang

et al. 2022

World J Surg Onc

View full text Add to dashboard Cite

show abstract

“…Intense investigation of molecular alterations involved in different steps of invasion, progression, and metastases of UCB has revealed various promising tissue-, blood, and urine-based biomarkers as predictors for outcome in different bladder cancer settings [ 33 , 34 , 35 , 36 , 37 , 38 ]. Several predictive and prognostic models have been designed, but to this point none of these have reached a sufficient level of discrimination to allow implementation in daily clinical practice [ 37 , 39 , 40 , 41 , 42 , 43 ].…”

Section: Discussionmentioning

confidence: 99%

Circulating Forms of Urokinase-Type Plasminogen Activator Receptor in Plasma Can Predict Recurrence and Survival in Patients with Urothelial Carcinoma of the Bladder

Dohn

Thind

Salling

et al. 2021

Cancers

View full text Add to dashboard Cite

Urothelial carcinoma of the bladder is a highly aggressive disease characterised by a very heterogeneous clinical outcome. Despite cystectomy, patients still have a high recurrence risk and shortened survival. Urokinase-type plasminogen activator receptor (uPAR) is present in tumour tissue specimens from patients with urothelial carcinoma. The different uPAR forms in blood are strong prognostic markers in other cancer types. We investigate the presence of different uPAR forms in tumour tissue and test the hypothesis that preoperative plasma levels of the uPAR forms predict recurrence free survival, cancer specific survival, and overall survival in patients treated with cystectomy for urothelial carcinoma. Using Western blotting we analyse neoplasia and adjacent benign-appearing urothelium from randomly selected patients for the presence of intact and cleaved uPAR forms. Prospectively collected preoperative plasma samples from 107 patients who underwent radical cystectomy for urothelial carcinoma are analysed. The different uPAR forms are measured by time-resolved fluorescence immunoassays. uPAR in tumour tissue from patients with urothelial carcinoma is demonstrated in both an intact and cleaved form. The different uPAR forms in plasma are all significantly associated with both recurrence free survival, cancer specific survival, and overall survival, high concentrations predicting short survival. uPAR (I) has the strongest association with a HR of 2.56 for overall survival. In the multivariable survival analysis uPAR (I) is significantly associated with cancer specific survival and overall survival.

show abstract

“…The 5-year overall survival rate of LN-positive patients is <30% [4] . Although several studies have indicated that predictive models incorporating genetic and clinical factors are useful in predicting the prognosis of UC, few studies have validated the utility of predictive models for the improvement of clinical decision-making [ 5 , 6 ]. Moreover, owing to the striking molecular heterogeneity, patients with UC with the same grade and stage might present distinct outcomes.…”

Section: Introductionmentioning

confidence: 99%

Identification of leucine-rich repeat-containing protein 59 (LRRC59) located in the endoplasmic reticulum as a novel prognostic factor for urothelial carcinoma

Pei

Zhu

Zhuang

et al. 2022

Translational Oncology

View full text Add to dashboard Cite

Prognostic Model for Predicting Survival in Patients with Disease Recurrence Following Radical Cystectomy

Cited by 7 publications

References 27 publications

Distant metastasis without regional progression in non-muscle invasive bladder cancer: case report and pooled analysis of literature

Distant metastasis without regional progression in non-muscle invasive bladder cancer: case report and pooled analysis of literature

Circulating Forms of Urokinase-Type Plasminogen Activator Receptor in Plasma Can Predict Recurrence and Survival in Patients with Urothelial Carcinoma of the Bladder

Identification of leucine-rich repeat-containing protein 59 (LRRC59) located in the endoplasmic reticulum as a novel prognostic factor for urothelial carcinoma

Contact Info

Product

Resources

About